• Underlying EBITDA increased 3.2% to $300 million
• Healthcare EBITDA grew 1.3%, Animal Care EBITDA increased 15.1%
• Confident in H2 FY26 EBITDA delivery, supported by new opportunities

EBOS Group Limited today reported its interim results to 31 December 2025 (HY26), delivering strong revenue growth of 13.0% and disciplined execution. FY26 EBITDA guidance was reaffirmed with further improvement expected as productivity and utilisation continue to increase and ongoing solid demand across key healthcare and animal care markets. Underlying EBITDA increased 3.2% to $300 million, consistent with guidance and commissioning of strategic investments. Healthcare EBITDA grew 1.3% to $254 million, with strong revenue momentum and disciplined cost management. Animal Care EBITDA increased 15.1% to $68 million, driven by good branded performance, cost management and the successful acquisition of SVS. EBOS retains confidence in H2 FY26 EBITDA delivery, underpinned by opportunities in Healthcare from progress in the DC renewal program, additional runway from the newly acquired MediAdvice pharmacy network banner, benefits from recent Medical Technology acquisitions and a strong product pipeline in Animal Care. The Board maintained the interim dividend, consistent with capital management priorities and confidence in the Group's outlook.

FY26 EBITDA guidance is reaffirmed, reflecting a positive outlook on H2 EBITDA as productivity and utilisation continues to increase, and with strong revenue growth supported by acquisitions.

Revenue momentum to continue, driven by network growth across retail pharmacy brands, innovation led growth within Animal Care products, and regional expansion and solution opportunities within Medical Technology. Margin outlook positive, driven by productivity uplift & improved utilisation in Healthcare, expanded CSO regime, and ongoing benefit from business mix shift. Interest and D&A expected to normalise, with peak capex in FY26 and a more stable asset base from FY27 onwards. Capex to reduce by ~30% in FY27, following completion of the DC renewal program, supporting stronger cash flows. Balance sheet leverage expected to reduce in FY27, reflecting lower capex, revenue growth and improved operating efficiency.